I keep coming back to a frustrating paradox in oncology: the science is sprinting, but clinical adoption still feels like it’s stuck on a treadmill. Companion diagnostics—those biomarker tests that tell doctors which therapies will actually work—are often treated like a “nice-to-have” afterthought instead of the operational backbone of precision medicine. Personally, I think that mismatch is not just an implementation problem; it’s a systems problem, and it reveals how healthcare struggles to translate evidence into action at the speed patients deserve.
What makes this particularly fascinating is that we already know what’s needed: molecular profiling, validated biomarkers, reliable assays, and fast workflows. Yet the distance between “we can do it” and “we do it routinely” remains stubbornly wide. In my opinion, the delay isn’t caused by a lack of intelligence—it's caused by incentives, timelines, and risk tolerance colliding across regulators, labs, payers, and pharma. If you take a step back and think about it, companion diagnostics become a stress test for the whole healthcare value chain.
Companion diagnostics as the real infrastructure
Companion diagnostics sit at the intersection of pathology, drug development, and patient access, but many people still frame them as a technical add-on. Personally, I see them more like infrastructure: without them, targeted therapies can’t reliably connect to the right patients, and “precision” becomes marketing language rather than clinical reality.
The core factual point is straightforward: CDx helps identify actionable molecular targets and supports targeted treatment decisions, often using next-generation sequencing (NGS). But what people often misunderstand is the kind of coordination CDx demands. It forces multiple domains—clinical evidence generation, test manufacturing/validation, clinical workflow design, and reimbursement logic—to move together.
One thing that immediately stands out is how much CDx asks healthcare systems to change without paying them to change. Laboratories need standardized, clinical-grade processes; clinicians need clear interpretability; administrators need workflow integration; and payers need coverage rationales built on outcomes, not just analytic performance. What this really suggests is that diagnostic adoption is fundamentally about governance and operational design—not just technology.
From my perspective, the “bridge” metaphor is apt, but only if we treat the bridge as a shared project with shared accountability. Otherwise, the bridge becomes a toll road: pharma has leverage during development, diagnostics have leverage during validation, providers have leverage during workflow, and payers have leverage at the final checkpoint. When each party optimizes locally, the patient experiences delay as the default outcome.
The bottlenecks nobody wants to own
The path from biomarker discovery to routine use is slow, and the reasons are annoyingly practical. Evidence generation comes first: biomarkers require clinical validity and utility, which often means large-scale validation, prospective trials, and multi-center work. For predictive biomarkers, the timeline can run for years—sometimes roughly 5 to 10 years—before broad adoption becomes feasible.
Personally, I think the biggest problem with this timeline is psychological rather than scientific. Teams can point to “regulatory rigor” as the explanation and still miss the deeper reality: patients don’t experience delays as “due diligence.” They experience them as lost decision windows, progression risk, and missed trial or treatment opportunities.
Next comes the gap between research-grade and clinical-grade assays. In academic or specialist settings, assays can be handled by expert users using flexible protocols. But routine care demands validated processes: automation, reproducibility, and rigorous analytical validation to achieve in vitro diagnostic (IVD) status. This step requires investment, and it’s where many promising tools quietly stall.
What many people don’t realize is that validation is not just a regulatory checkbox; it’s a translation of fragile performance into resilient consistency. A sequencing platform that performs beautifully in one environment may behave differently across sites due to sample handling, reagent lots, operator variation, and pre-analytical factors. From my perspective, that’s why adoption feels uneven: the “last mile” is where variability lives.
Finally, reimbursement becomes the gatekeeper. Insurers typically demand evidence of clinical utility and cost-effectiveness before they’ll cover a novel diagnostic broadly. And when alignment among payers, pharma, medical societies, and regulators takes years, even clinically proven tests can end up stuck in pilots or niche settings.
In my opinion, reimbursement delays are often treated like a business detail, but they function like a clinical delay mechanism. Coverage uncertainty changes provider behavior: clinicians avoid ordering tests they can’t reliably bill for, labs hesitate to scale workflows, and patients quietly lose access. This raises a deeper question: if the science says “treat,” why is the payment system allowed to say “wait” for years?
Why pharma–diagnostic collaboration matters more than partnerships-as-usual
The editorial temptation is to say “collaboration is good,” but I think the real story is more specific: CDx adoption requires synchronized development across stakeholders, not just occasional coordination. No single actor can close the translation gap alone—diagnostic developers, drug companies, providers, and regulators all hold pieces of the puzzle.
From my perspective, the shift that matters most is moving diagnostic companies from being purely technology providers to becoming clinical solution partners. That means designing for deployment: automated platforms, user-friendly operation, reproducibility, and interpretability that fits real clinic constraints. An FDA-approved IVD platform can reduce some validation burden for hospitals and increase clinician confidence, which indirectly improves adoption speed.
What makes this particularly fascinating is how CDx and NGS converge into an ecosystem. When diagnostic and drug pipelines move in sync, biomarker-driven trials can run more efficiently, regulatory submissions can be coordinated, and reimbursement conversations become clearer because clinical utility aligns with an approved therapy.
Personally, I think the “parallel validation” concept is the breakthrough people intuitively want but often fail to execute. If therapy approval arrives while companion test validation lags, patients still get stuck at the border crossing. The joint model tries to eliminate that lag so patients can be tested and treated immediately after therapy approval.
This also connects to a bigger trend: decentralization. Distributed IVD-based CDx platforms can be adapted to local regulatory requirements and supported across lab networks, which matters in markets where centralized testing is less viable. In other words, global scalability isn’t only a manufacturing question—it’s a network and training question too.
Turnaround time: the most humane metric
Clinically, speed isn’t just convenience; it’s decision-making oxygen. For patients, especially right after diagnosis, time can affect eligibility for therapies, the ability to enroll in trials, and the overall treatment trajectory.
Factually, NGS-based CDx can test multiple genetic mutations simultaneously, avoiding the sequential bottleneck of single-biomarker testing. And some platforms can deliver results in as little as 24 hours, which can meaningfully accelerate care decisions.
Personally, I think people often underestimate how tissue and time scarcity shape outcomes. Sequential single tests can consume valuable tumor material and sometimes force repeat biopsies, which add risk, cost, and delay. A rapid multi-marker workflow doesn’t just speed reporting—it can reduce the need for “re-starting” a diagnostic journey.
From my perspective, faster turnaround time changes clinical behavior too. When results might arrive within days, clinicians can adjust treatment trajectories quickly rather than waiting for slow feedback loops. For pharmaceutical companies, it can also strengthen patient identification and trial enrollment, reducing the likelihood that patients drift into suboptimal treatment paths.
One thing that immediately stands out is that speed depends on coordination. Early alignment between pharma and diagnostics partners helps streamline validation and regulatory processes, but speed in practice also requires operational readiness: sample logistics, ordering workflows, and lab turnaround discipline.
The deeper lesson: adoption is an ecosystem, not a product
If I were to boil it down, companion diagnostics expose a recurring healthcare pattern: innovation gets treated like an invention problem, when it’s actually an adoption problem. The science may be impressive, but adoption depends on evidence generation, workflow integration, and reimbursement alignment—all under real-world constraints.
Personally, I think the industry is trapped in a cycle of fragmented implementation because each stakeholder has valid reasons to move cautiously. Regulators want certainty. Labs want operational stability. Payers want economic proof. Pharma wants timeline control. But patients don’t live in those timelines.
What this really suggests is that “closing the gap” requires more than better tests—it requires better systems design. That means designing diagnostic programs as clinical services, aligning development timelines with coverage and workflow realities, and treating turnaround time as a measure of clinical impact rather than a feature.
And there’s a final, slightly uncomfortable implication: if adoption keeps lagging, precision medicine becomes uneven by default. That affects equity, because community hospitals often face the largest adoption gaps. When precision tools don’t scale, the promise of personalization doesn’t land evenly—it concentrates.
A provocative takeaway
Personally, I don’t think the question is whether companion diagnostics work. They do, and the evidence base keeps growing. The question is whether our healthcare ecosystem is willing to reorganize around them—so that “precision” becomes a routine clinical workflow, not a reward for patients in the right place at the right time.
If we truly want precision oncology to deliver on its promise, we should stop treating CDx adoption as a slow administrative afterthought. We should treat it as a core clinical pathway—one that gets planned, funded, validated, and integrated with the urgency patients feel.
